WO2013082302A1 - Agomelatine-urea complex and crystalline forms thereof - Google Patents

Agomelatine-urea complex and crystalline forms thereof Download PDF

Info

Publication number
WO2013082302A1
WO2013082302A1 PCT/US2012/067098 US2012067098W WO2013082302A1 WO 2013082302 A1 WO2013082302 A1 WO 2013082302A1 US 2012067098 W US2012067098 W US 2012067098W WO 2013082302 A1 WO2013082302 A1 WO 2013082302A1
Authority
WO
WIPO (PCT)
Prior art keywords
agomelatine
urea
urea complex
complex according
complex
Prior art date
Application number
PCT/US2012/067098
Other languages
French (fr)
Inventor
Sven HAFERKAMP
Roland Boese
Original Assignee
Ratiopharm Gmbh
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh, Teva Pharmaceuticals Usa, Inc. filed Critical Ratiopharm Gmbh
Priority to EP12799022.4A priority Critical patent/EP2771312B1/en
Priority to ES12799022.4T priority patent/ES2634243T3/en
Publication of WO2013082302A1 publication Critical patent/WO2013082302A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/02—Salts; Complexes; Addition compounds

Definitions

  • the present invention concerns an Agomelatine-urea complex, solid state forms of said Agomelatine-urea complex, processes for their preparation, and pharmaceutical compositions comprising an Agomelatine-urea complex or a solid state form thereof.
  • Agomelatine is marketed under the tradenames Valdoxan and Thymanax .
  • Agomelatine is an antidepressant developed for the treatment of major depressive disorder.
  • Agomelatine has been reported to have a reduced level of sexual side effects as well as discontinuation effects, as compared to some other antidepressants.
  • Agomelatine may also have positive effects on sleep.
  • EP 1752445, EP2008993 and EP2210872 disclose Form III of Agomelatine.
  • European patent nos. EP 1752444 and EP2008994 disclose Form IV of Agomelatine.
  • European patent nos. EP1752443 and EP2277857 disclose Form V of Agomelatine.
  • EP2058296 and Chinese patent no. CN101585779 disclose Form VI of Agomelatine.
  • Chinese patent no. CN101955440 discloses Form X of Agomelatine.
  • Chinese patent no. CN101723844 discloses Form B of Agomelatine.
  • Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
  • a single molecule like Agomelatine, may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by capillary melting point, thermogravimetric analysis (TGA), or differential scanning calorimetry (DSC), as well as content of solvent in the polymorphic form), powder x-ray diffraction pattern ("PXRD” or “powder XRD”), infrared absorption and Raman fingerprints, and solid state NMR spectrum.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • One or more of these techniques may thus be used to characterize a particular solid state form and to distinguish different polymorphic forms of a compound. These techniques may also be used to quantify the amount of one or more crystalline forms in a mixture. The differences in the physical properties of different polymorphic forms result from the orientation and
  • polymorphs are distinct solids sharing the same molecular formula yet having distinct physico-chemical properties compared to other polymorphic forms of the same compound or complex.
  • a co-crystal is a molecular complex with a crystalline structure composed of at least two components, wherein the components may be atoms, ions or molecules.
  • a co-crystal consists of two or more components that form a unique crystalline structure having unique properties.
  • a co-crystal structure exhibits long-range order and the components interact via non-covalent interactions such as hydrogen bonding, ionic interactions, van der Waals interactions and n-interactions.
  • the present invention provides an Agomelatine -urea complex, isolated and/or solid state forms of the Agomelatine-urea complex, and pharmaceutical compositions comprising said Agomelatine-urea complex and at least one pharmaceutically acceptable excipient.
  • the Agomelatine-urea complex comprises co-crystals of Agomelatine and urea.
  • the Agomelatine-urea complex comprises co-crystals of Agomelatine and urea in which the Agomelatine and urea are in a stoichiometry of about 1 : 1 , or exactly 1 : 1.
  • the agomelatine urea complex is an agomelatine urea co-crystal.
  • the invention further provides the use of the Agomelatine-urea complex, and the solid state forms of the Agomelatine-urea complex described below, in the manufacture of a pharmaceutical composition.
  • the invention further provides the use of the Agomelatine-urea complex, and the solid state forms of the Agomelatine-urea complex described below, for the manufacture of a medicament for the treatment of depression.
  • the invention further provides a method of treatment of depression comprising administering a therapeutically effective dose of the Agomelatine-urea complex or a crystalline form thereof to a person suffering from depression.
  • the invention also provides a method for treating depression comprising administering a pharmaceutical composition comprising an Agomelatine-urea complex, or a crystalline form thereof, and at least one pharmaceutically acceptable excipient.
  • Figure 1 shows a powder XRD pattern of crystalline Agomelatine-urea complex.
  • Figure 2 shows the interaction of Agomelatine and urea in crystalline Agomelatine- urea complex.
  • Figure 3 shows a 13 C CPMAS NMR spectrum of crystalline Agomelatine-urea complex.
  • a crystal form may be referred to herein as being characterized by graphical data "as shown in,” or “as depicted in,” or “substantially as depicted in” a Figure.
  • Such data include, for example, powder X-ray diffractograms and solid state NMR spectra.
  • the graphical data potentially provides additional technical information to further define the respective solid state form which can not necessarily be described by reference to numerical values or peak positions.
  • the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample
  • the crystal form characterized by the graphical data "as shown in,” or “as depicted in,” or “substantially as depicted in” a Figure disclosed herein includes a crystal form characterized by graphical data with small variations, which are well known to the skilled person, in comparison to the graphical data in the Figure.
  • a crystal form (also referred to herein as a crystalline form or a polymorph) may be referred to herein as pure or polymorphically pure, or substantially free of any other crystalline or polymorphic forms.
  • substantially free will be understood to mean that the crystalline form contains 20% or less, 10%) or less, 5% or less, 2% or less, or 1% or less of any other crystalline forms of the subject compound as measured, for example, by PXRD.
  • crystalline forms of Agomelatine- urea complex described herein as substantially free of any other crystalline forms would be understood to contain greater than 80%> (w/w), greater than 90%> (w/w), greater than 95% (w/w), greater than 98% (w/w), or greater than 99% (w/w) of the subject crystalline form of Agomelatine-urea complex.
  • the described crystalline form may contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w) of one or more other crystal forms of the same complex.
  • a thing e.g., a reaction mixture
  • room temperature or “ambient temperature”, often abbreviated "RT.”
  • RT room temperature
  • room or ambient temperature is from about 15°C to about 30°C, or about 20°C to about 25°C, or about 25°C.
  • the term "complex” refers to a molecular entity formed by association involving two or more component molecular entities (ionic or uncharged), or by association involving two or more chemical species.
  • the bonding between the components is non- covalent and is normally weaker than covalent bonding.
  • the Agomelatine-urea complex described herein is a molecular entity formed by the association between
  • the Agomelatine-urea complex may in some embodiments exist as a solid state form that is referred to herein as a co-crystal form of an Agomelatine-urea complex, or as an Agomelatine-urea co-crystal, or as a crystalline Agomelatine-urea complex.
  • Co-crystals of Agomelatine are crystalline structures composed of Agomelatine and at least one other component. Agomelatine co-crystals form unique crystalline structures having unique properties. The intermolecular interactions in the co-crystals generate physical and chemical properties that differ from the properties of the individual components. Such properties include bioavailability, melting point, solubility, chemical stability, and
  • Agomelatine co-crystals can exhibit polymorphism.
  • the Agomelatine Urea complex of the present invention is reproducible and also stable during storage. For example, at 25°C / 60% relative humidity, or at 30°C / 65%> relative humidity, or at 40°C / 75% relative humidity, the Agomelatine-urea complex of the present invention remained stable for at least 162 days.
  • the Agomelatine-urea complex exhibits significantly enhanced solubility and enhanced rate of dissolution, compared to the moderately soluble Agomelatine Form II.
  • the enhanced solubility which is apparently facilitated by the stoichoimetric incorporation of the highly soluble urea into the Agomelatine crystal lattice, constitutes an important advantage, in particular in sublingual formulations.
  • the Agomelatine-urea complex may also improve stability and shelf-life of the API, or give rise to improved processing or handling properties during formulation.
  • the complex may also provide improvements for the final dosage form, for instance by improving the dissolution profile, or bioavailability of the finished product, or by improving the shelf life of the finished dosage form.
  • the Agomelatine-urea complex of the present invention can be present in isolated form or be in a solution.
  • the urea and agomelatine molecules are present in the complex at an about equimolar ratio (i.e. a 1 : 1 stoichiometry of urea and agomelatine).
  • excess urea may be present in the Agomelatine-urea complex
  • the present invention also provides a crystalline form of the Agomelatine-urea complex.
  • a person skilled in the art would be able to characterize the above crystalline form by identifying one or more characteristic peaks in a powder X-ray diffraction analysis of that form.
  • the skilled person would be able to characterize the above form by selecting one or more characteristic peaks in the diffractogram provided in Figure 1.
  • the crystalline form of the Agomelatine-urea complex is characterized by data selected from: a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2 ⁇ ⁇ 0.2° 2 ⁇ ; a powder XRD pattern substantially as depicted in Figure 1; a solid state 13 C NMR spectrum with peaks at 21.4, 54.7, 130.4, 133.8, 157.4, 172.6, 199.7, and 203.7 ppm; a 13 C NMR spectrum substantially as depicted in Figure 3; and any combinations thereof.
  • the crystalline form of the Agomelatine-urea complex is characterized by a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2 ⁇ ⁇ 0.2° 2 ⁇ ; or a powder XRD pattern substantially as depicted in Figure 1; or a solid state 13 C NMR spectrum with peaks at 21.4, 54.7, 130.4, 133.8, 157.4, 172.6, 199.7, and 203.7 ppm; or a 13 C NMR spectrum substantially as depicted in Figure 3; or any combinations thereof.
  • the crystalline form of the Agomelatine-urea complex can be characterized by a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2 ⁇ ⁇ 0.2° 2 ⁇ , and one or more additional peak(s) selected from the following peaks: 18.41°, 19.28°, 20.72°, 27.74°, and 31.26° 2 ⁇ ⁇ 0.2° 2 ⁇ .
  • the crystalline Agomelatine-urea complex is characterized by the following atomic coordinates in the above-defined unit cell (see my comments below).
  • the Agomelatine-urea complex can be prepared, for example, by a process comprising co-milling Agomelatine with urea until the molecular complex of Agomelatine and urea is formed.
  • the crystalline Agomelatine-urea complex may also be prepared by slow evaporation of a saturated solution of the Agomelatine-urea complex in a suitable solvent, such as ethanol, at ambient temperature.
  • the above mentioned Agomelatine-urea complex can inter alia be used to prepare Agomelatine polymorphs, for example, Agomelatine Form II, as described in EP 1564202, or it can be used to prepare other complexes of Agomelatine.
  • the Agomelatine-urea complex can also be used to prepare pharmaceutical compositions.
  • the present invention further encompasses 1) a pharmaceutical composition comprising the Agomelatine-urea complex or crystalline form thereof, as described above, and at least one pharmaceutically acceptable excipient; and 2) a process for preparing the pharmaceutical composition comprising combining the above mentioned Agomelatine-urea complex or the particular solid state form thereof, and at least one acceptable excipient.
  • the pharmaceutical composition can be used as a medicament, for example for treating depression.
  • the samples were, if necessary, ground in an agate mortar and prepared on a flat specimen holder made from a silicon single crystal.
  • Measurements were performed on a Bruker AXS D8 Advance powder X-ray diffractometer (Bruker AXS, Düsseldorf, Germany). The specimen holder was rotated in the zO plane at 20 rpm during measurement. The measurement conditions were as follows: Radiation CuK a i of wavelength 1.54184 A , Source 40 kV / 40 mA, detector: PSD-LynxEye Range 4° 2 ⁇ ;
  • the solution was filtered hot through a folded filter into a flask
  • a single crystal of the Agomelatine-urea complex which was suitable for X-ray diffraction measurement, was obtained by slow evaporation of a solution of the Agomelatine- urea co-crystal in ethanol at room temperature. The measurement was performed on a Rigaku XtaLab mini diffractometer at 293K. Crystallographic data are given below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides an Agomelatine-urea complex, and a specific crystalline form thereof.

Description

AGOMELATINE-UREA COMPLEX AND CRYSTALLINE FORMS THEREOF
CROSS REFERENCE TO RELATED APPLICATION
This patent application claims the benefit of U.S. Provisional Application No.
61/565,224, filed November 30, 2011, the disclosure of which is hereby incorporated by reference.
FIELD OF INVENTION
The present invention concerns an Agomelatine-urea complex, solid state forms of said Agomelatine-urea complex, processes for their preparation, and pharmaceutical compositions comprising an Agomelatine-urea complex or a solid state form thereof.
BACKGROUND OF THE INVENTION
Agomelatine, N-[2-(7-methoxynaphthalen-l-yl)ethyl]acetamide, has the structural formula:
Figure imgf000002_0001
Agomelatine is marketed under the tradenames Valdoxan and Thymanax . Agomelatine is an antidepressant developed for the treatment of major depressive disorder. Agomelatine has been reported to have a reduced level of sexual side effects as well as discontinuation effects, as compared to some other antidepressants. Agomelatine may also have positive effects on sleep.
Agomelatine, its preparation and its use are disclosed in U.S. patent no. 5,225,442. European patent no. EP 1564202 discloses Form II of Agomelatine. European patent nos.
EP 1752445, EP2008993 and EP2210872 disclose Form III of Agomelatine. European patent nos. EP 1752444 and EP2008994 disclose Form IV of Agomelatine. European patent nos. EP1752443 and EP2277857 disclose Form V of Agomelatine. European patent no.
EP2058296 and Chinese patent no. CN101585779 disclose Form VI of Agomelatine. Chinese patent no. CN101955440 discloses Form X of Agomelatine. Chinese patent no. CN101723844 discloses Form B of Agomelatine.
Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, like Agomelatine, may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by capillary melting point, thermogravimetric analysis (TGA), or differential scanning calorimetry (DSC), as well as content of solvent in the polymorphic form), powder x-ray diffraction pattern ("PXRD" or "powder XRD"), infrared absorption and Raman fingerprints, and solid state NMR spectrum. The differences in physical properties have been used to distinguish polymorphic forms. One or more of these techniques may thus be used to characterize a particular solid state form and to distinguish different polymorphic forms of a compound. These techniques may also be used to quantify the amount of one or more crystalline forms in a mixture. The differences in the physical properties of different polymorphic forms result from the orientation and
intermolecular interactions of adjacent molecules or complexes in the bulk solid.
Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct physico-chemical properties compared to other polymorphic forms of the same compound or complex.
A co-crystal is a molecular complex with a crystalline structure composed of at least two components, wherein the components may be atoms, ions or molecules. A co-crystal consists of two or more components that form a unique crystalline structure having unique properties. A co-crystal structure exhibits long-range order and the components interact via non-covalent interactions such as hydrogen bonding, ionic interactions, van der Waals interactions and n-interactions.
The discovery of new polymorphic forms and co-crystals of Agomelatine can provide new ways to improve the synthesis and the characteristics of Agomelatine as an active pharmaceutical ingredient.
SUMMARY OF THE INVENTION
The present invention provides an Agomelatine -urea complex, isolated and/or solid state forms of the Agomelatine-urea complex, and pharmaceutical compositions comprising said Agomelatine-urea complex and at least one pharmaceutically acceptable excipient.
According to some embodiments of the present invention, the Agomelatine-urea complex comprises co-crystals of Agomelatine and urea. According to some sub- embodiments thereof, the Agomelatine-urea complex comprises co-crystals of Agomelatine and urea in which the Agomelatine and urea are in a stoichiometry of about 1 : 1 , or exactly 1 : 1. In a more preferred embodiment, the agomelatine urea complex is an agomelatine urea co-crystal.
The invention further provides the use of the Agomelatine-urea complex, and the solid state forms of the Agomelatine-urea complex described below, in the manufacture of a pharmaceutical composition. The invention further provides the use of the Agomelatine-urea complex, and the solid state forms of the Agomelatine-urea complex described below, for the manufacture of a medicament for the treatment of depression. The invention further provides a method of treatment of depression comprising administering a therapeutically effective dose of the Agomelatine-urea complex or a crystalline form thereof to a person suffering from depression. The invention also provides a method for treating depression comprising administering a pharmaceutical composition comprising an Agomelatine-urea complex, or a crystalline form thereof, and at least one pharmaceutically acceptable excipient.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows a powder XRD pattern of crystalline Agomelatine-urea complex. Figure 2 shows the interaction of Agomelatine and urea in crystalline Agomelatine- urea complex.
Figure 3 shows a 13C CPMAS NMR spectrum of crystalline Agomelatine-urea complex.
DETAILED DESCRIPTION OF THE INVENTION
A crystal form may be referred to herein as being characterized by graphical data "as shown in," or "as depicted in," or "substantially as depicted in" a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. The graphical data potentially provides additional technical information to further define the respective solid state form which can not necessarily be described by reference to numerical values or peak positions. In any event, the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample
concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figure disclosed herein with graphical data generated for an unknown crystal form, and confirm whether the two sets of data are characterizing the same crystal form or two different crystal forms. The crystal form characterized by the graphical data "as shown in," or "as depicted in," or "substantially as depicted in" a Figure disclosed herein includes a crystal form characterized by graphical data with small variations, which are well known to the skilled person, in comparison to the graphical data in the Figure.
A crystal form (also referred to herein as a crystalline form or a polymorph) may be referred to herein as pure or polymorphically pure, or substantially free of any other crystalline or polymorphic forms. As used herein in this context, the expression
"substantially free" will be understood to mean that the crystalline form contains 20% or less, 10%) or less, 5% or less, 2% or less, or 1% or less of any other crystalline forms of the subject compound as measured, for example, by PXRD. Thus, crystalline forms of Agomelatine- urea complex described herein as substantially free of any other crystalline forms would be understood to contain greater than 80%> (w/w), greater than 90%> (w/w), greater than 95% (w/w), greater than 98% (w/w), or greater than 99% (w/w) of the subject crystalline form of Agomelatine-urea complex. Accordingly, in some embodiments of the invention, the described crystalline form may contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w) of one or more other crystal forms of the same complex.
A thing, e.g., a reaction mixture, may be characterized herein as being at, or allowed to come to "room temperature" or "ambient temperature", often abbreviated "RT." This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room or ambient temperature is from about 15°C to about 30°C, or about 20°C to about 25°C, or about 25°C.
As used herein, the term "complex" refers to a molecular entity formed by association involving two or more component molecular entities (ionic or uncharged), or by association involving two or more chemical species. The bonding between the components is non- covalent and is normally weaker than covalent bonding. Accordingly, the Agomelatine-urea complex described herein is a molecular entity formed by the association between
Agomelatine and urea. The Agomelatine-urea complex may in some embodiments exist as a solid state form that is referred to herein as a co-crystal form of an Agomelatine-urea complex, or as an Agomelatine-urea co-crystal, or as a crystalline Agomelatine-urea complex.
Co-crystals of Agomelatine are crystalline structures composed of Agomelatine and at least one other component. Agomelatine co-crystals form unique crystalline structures having unique properties. The intermolecular interactions in the co-crystals generate physical and chemical properties that differ from the properties of the individual components. Such properties include bioavailability, melting point, solubility, chemical stability, and
mechanical properties. Agomelatine co-crystals can exhibit polymorphism.
All of the Agomelatine crystalline forms which were disclosed in the above mentioned publications, except for Form II as disclosed in EP 1564202, were found to be unstable during storage, whereupon they transformed into Form II, or they found to be not reproducible.
The Agomelatine Urea complex of the present invention is reproducible and also stable during storage. For example, at 25°C / 60% relative humidity, or at 30°C / 65%> relative humidity, or at 40°C / 75% relative humidity, the Agomelatine-urea complex of the present invention remained stable for at least 162 days.
In addition, the Agomelatine-urea complex exhibits significantly enhanced solubility and enhanced rate of dissolution, compared to the moderately soluble Agomelatine Form II. The enhanced solubility, which is apparently facilitated by the stoichoimetric incorporation of the highly soluble urea into the Agomelatine crystal lattice, constitutes an important advantage, in particular in sublingual formulations.
The Agomelatine-urea complex may also improve stability and shelf-life of the API, or give rise to improved processing or handling properties during formulation. The complex may also provide improvements for the final dosage form, for instance by improving the dissolution profile, or bioavailability of the finished product, or by improving the shelf life of the finished dosage form.
In light of the above, Agomelatine urea might have superior alternative to
Agomelatine Form II.
In one aspect, the present invention provides an Agomelatine-urea complex.
The Agomelatine-urea complex of the present invention can be present in isolated form or be in a solution. Preferably, the urea and agomelatine molecules are present in the complex at an about equimolar ratio (i.e. a 1 : 1 stoichiometry of urea and agomelatine). In other embodiments, excess urea may be present in the Agomelatine-urea complex
The present invention also provides a crystalline form of the Agomelatine-urea complex. A person skilled in the art would be able to characterize the above crystalline form by identifying one or more characteristic peaks in a powder X-ray diffraction analysis of that form. For example, the skilled person would be able to characterize the above form by selecting one or more characteristic peaks in the diffractogram provided in Figure 1. Accordingly, the crystalline form of the Agomelatine-urea complex is characterized by data selected from: a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2Θ ±0.2° 2Θ; a powder XRD pattern substantially as depicted in Figure 1; a solid state 13C NMR spectrum with peaks at 21.4, 54.7, 130.4, 133.8, 157.4, 172.6, 199.7, and 203.7 ppm; a 13C NMR spectrum substantially as depicted in Figure 3; and any combinations thereof.
Alternatively, the crystalline form of the Agomelatine-urea complex is characterized by a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2Θ ±0.2° 2Θ; or a powder XRD pattern substantially as depicted in Figure 1; or a solid state 13C NMR spectrum with peaks at 21.4, 54.7, 130.4, 133.8, 157.4, 172.6, 199.7, and 203.7 ppm; or a 13C NMR spectrum substantially as depicted in Figure 3; or any combinations thereof.
Alternatively, the crystalline form of the Agomelatine-urea complex can be characterized by a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2Θ ±0.2° 2Θ, and one or more additional peak(s) selected from the following peaks: 18.41°, 19.28°, 20.72°, 27.74°, and 31.26° 2Θ ±0.2° 2Θ.
The crystalline Agomelatine-urea complex can further be characterized by a single crystal X-ray structure having a monoclinic unit cell; symmetry space group P2i/n having the parameters at 293 K approximately equal to the following: a=9.709(15) A, b= 9.263(13) A, c= 18.71(3) A, alpha = 90°, beta = 101.79(2)°, gamma = 90°; and Volume = 1647(4) A3.
In one embodiment, the crystalline Agomelatine-urea complex is characterized by the following atomic coordinates in the above-defined unit cell (see my comments below).
Figure imgf000007_0001
C(13) 7681(3) 6555(3) -1239(1) 58(1)
C(14) 8547(3) 6681(3) -461(1) 55(1)
C(15) 7343(3) 5349(3) 353(1) 56(1)
C(16) 6462(3) 5425(3) 928(2) 78(1)
N(l) 8254(3) 1065(2) 917(1) 79(1)
N(2) 6145(3) 1537(2) 171(1) 84(1)
N(3) 7701(2) 6597(2) 99(1) 57(1)
0(1) 6684(2) -725(2) 586(1) 66(1)
0(2) 9515(2) 1286(2) -1471(1) 79(1)
0(3) 7698(2) 4177(2) 124(1) 74(1)
H(1A) 8843 485 1177 95
H(1B) 8463 1963 890 95
H(2A) 5330 1274 -67 101
H(2B) 6403 2424 161 101
H(3A) 7427 7385 270 68
H(3B) 10958 1770 -2406 92
H(4A) 11341 3849 -2965 93
H(7A) 8511 3839 -1242 69
H(9A) 8437 8581 -2065 81
H(10A) 9932 8591 -2887 97
H(l 1 A) 10972 6493 -3154 93
H(12A) 8523 208 -825 124
H(12B) 7625 1457 -1254 124
H(12C) 8838 1816 -586 124
H(13A) 7108 5690 -1279 70
H(13B) 7055 7379 -1343 70
H(14A) 9243 5915 -380 65
H(14B) 9048 7594 -413 65
H(16A) 6262 4465 1072 117
H(16B) 5595 5916 734 117
H(16C) 6967 5941 1345 117
Figure imgf000009_0001
The Agomelatine-urea complex can be prepared, for example, by a process comprising co-milling Agomelatine with urea until the molecular complex of Agomelatine and urea is formed. The crystalline Agomelatine-urea complex may also be prepared by slow evaporation of a saturated solution of the Agomelatine-urea complex in a suitable solvent, such as ethanol, at ambient temperature.
The above mentioned Agomelatine-urea complex can inter alia be used to prepare Agomelatine polymorphs, for example, Agomelatine Form II, as described in EP 1564202, or it can be used to prepare other complexes of Agomelatine.
In addition, the Agomelatine-urea complex can also be used to prepare pharmaceutical compositions. Hence, the present invention further encompasses 1) a pharmaceutical composition comprising the Agomelatine-urea complex or crystalline form thereof, as described above, and at least one pharmaceutically acceptable excipient; and 2) a process for preparing the pharmaceutical composition comprising combining the above mentioned Agomelatine-urea complex or the particular solid state form thereof, and at least one acceptable excipient.
The pharmaceutical composition can be used as a medicament, for example for treating depression.
Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the present specification. The invention is further defined by reference to the following examples which should not be construed as limiting the scope of the present invention. The examples describe in detail the preparation of the complex and the compositions and further uillustrate the uses and processes involving the Agomelatine-urea complex as described herein.. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the spirit and scope of the invention.
EXAMPLES
PXRD method
For powder XRD characterization, the samples were, if necessary, ground in an agate mortar and prepared on a flat specimen holder made from a silicon single crystal.
Measurements were performed on a Bruker AXS D8 Advance powder X-ray diffractometer (Bruker AXS, Karlsruhe, Germany). The specimen holder was rotated in the zO plane at 20 rpm during measurement. The measurement conditions were as follows: Radiation CuKai of wavelength 1.54184 A , Source 40 kV / 40 mA, detector: PSD-LynxEye Range 4° 2Θ;
monochromator: Johansson Germanium Single Crystal; scan range of 3° - 50° 2Θ; step width of 0.00922° 2Θ; and measuring time of 10 sec/step. Raw data were evaluated using the program EVA (Bruker- AXS, Karlsruhe, Germany).
Solid state NMR method
The 13C CPMAS NMR spectra were recorded at transmitter frequencies of 400.13
MHz and 100.639 MHz for 1H and 13C on a Bruker ASX400 NMR spectrometer. A standard 7 mm Bruker MAS probe was used at rotation frequencies of 7 kHz. The 90° pulse length for 1H was 9.0 (G3rf(1H) = G3rf(13C) = 28 kHz). The recycle delay was 30s. A total of 800 scans were accumulated and tetramethylsilane was used as reference for both 1H and 13C.
Example 1: Preparing of Agomelatine-urea complex
Agomelatine (Form II) and urea (0.308 mmol) were placed in a steel crucible containing a grinding ball (steel, d = 10 mm). The crucible was mounted on a Mini-Mill PULVERISETTE 23 (Fritsch) and the mixture was ground for 30 minutes at an oscillation rate of 50 Hz. The Agomelatine-urea co-crystal that was produced was colorless to slightly ocher, and was a fine crystalline powder. The product may be recrystallized by slow evaporation of a saturated solution of the Agomelatine-urea co-crystal in ethanol at ambient temperature. Example 2: Preparation of Agomelatine-Urea-cocrystals with seeding
Agomelatine (7.0 g, 28.8 mmol) and urea (1.75 g, 29.1 mmol) were dissolved in ethanol (20mL) at reflux temperature.
The solution was filtered hot through a folded filter into a flask
containing a small amount of seed crystals (Agomelatine-Urea-cocrystals, obtainable for example by the procedure of Example 1). Immediate crystallization occurred, a small part of the product already formed in the filter. After 2 hours at room temperature the crystallized solid was isolated by vacuum filtration, washed with a small amount of cold ethanol and dried at 35°C / 20 mbar overnight. A colourless coarse crystalline material was obtained (6.13 g, 70%), whose identity was confirmed by powder XRD, FT-IR, and DSC analysis.
Example 3: Preparing Form II
Sodium acetate (purity 98.5%, 35.32 g, 0.424 mol) and 2-(7-methoxy-l-naphthyl)- ethylamine hydrochloride (91.64 g, 0.385 mol) were suspended in ethanol (175 mL) at reflux temperature. Acetic acid anhydride (purity 98.5%, 39.21 mL, 0.409 mol) was added dropwise with stirring. The mixture was then refiuxed for 40 minutes. After addition of water (326 mL), the mixture was cooled to room temperature and stirred for 14 hours.
Agomelatine precipitated as polymorph II (86.16 g, 92%).
Example 4: Single crystal X-ray diffraction
A single crystal of the Agomelatine-urea complex, which was suitable for X-ray diffraction measurement, was obtained by slow evaporation of a solution of the Agomelatine- urea co-crystal in ethanol at room temperature. The measurement was performed on a Rigaku XtaLab mini diffractometer at 293K. Crystallographic data are given below.
Figure imgf000011_0001
Figure imgf000012_0001
Largest diff peak and hole 0.230 and -0.145 e "

Claims

Claims:
1. Agomelatine-urea com lex.
2. The Agomelatine-urea complex of claim 1 , which is isolated.
3. The Agomelatine-urea complex of claim 1 or claim 2, wherein the urea and
agomelatine molecules are present at an equimolar ratio (1 : 1).
4. A crystalline form of the Agomelatine-urea complex according to any one of claims 1 to 3, characterized by data selected from: a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2Θ ±0.2° 2Θ; a powder XRD pattern substantially as depicted in Figure 1; a solid state 13C NMR spectrum with peaks at 21.4, 54.7, 130.4, 133.8, 157.4, 172.6, 199.7, and 203.7 ppm; a 13C NMR spectrum substantially as depicted in Figure 3; and any combinations thereof.
5. The crystalline form of the Agomelatine-urea complex according to any one of claims 1 to 3, characterized by a powder XRD pattern with peaks at 9.52°, 13.28°, 15.51°, 21.30°, and 22.75° 2Θ ±0.2° 2Θ.
6. The crystalline form of the Agomelatine-urea complex according to any one of claims 1 to 3, characterized by a powder XRD pattern substantially as depicted in Figure 1.
7. The crystalline form of the Agomelatine-urea complex according to any one of claims 1 to 3, characterized by a solid state 13C NMR spectrum with peaks at 21.4, 54.7, 130.4, 133.8, 157.4, 172.6, 199.7, and 203.7 ppm.
8. The crystalline form of the Agomelatine-urea complex according to any one of claims 1 to 3, characterized by a 13C NMR spectrum substantially as depicted in Figure 3.
9. Use of Agomelatine-urea complex according to any one of claims 1 to 8 for the
preparation of Agomelatine, preferably for the preparation of Agomelatine Form II.
10. A pharmaceutical composition comprising the Agomelatine-urea complex according to any one of claims 1 to 8, and at least one pharmaceutically acceptable excipient.
11. Use of the Agomelatine-urea complex according to any one of claims 1 to 8 for the manufacture of a medicament.
12. A process for preparing a pharmaceutical composition comprising combining the Agomelatine-urea complex according to any one of claims 1 to 8 and at least one pharmaceutically acceptable excipient.
13. The Agomelatine-urea complex according to any one of claims 1 to 8 or the
pharmaceutical composition of claim 10 for use as a medicament.
14. The Agomelatine-urea complex according to any one of claims 1 to 8 or the
pharmaceutical composition of claim 10 for use in the treatment of depression.
15. A method for the treatment of depression comprising administering a therapeutically effective dose of (a) the Agomelatine-urea complex according to any one of claims 1 to 3, (b) a crystalline form thereof according to any one of claims 4 to 8, or (c) a pharmaceutical composition according to claim 10 to a person suffering from depression.
PCT/US2012/067098 2011-11-30 2012-11-29 Agomelatine-urea complex and crystalline forms thereof WO2013082302A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP12799022.4A EP2771312B1 (en) 2011-11-30 2012-11-29 Agomelatine-urea complex and crystalline forms thereof
ES12799022.4T ES2634243T3 (en) 2011-11-30 2012-11-29 Agomelatine-urea complex and crystalline forms thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161565224P 2011-11-30 2011-11-30
US61/565,224 2011-11-30

Publications (1)

Publication Number Publication Date
WO2013082302A1 true WO2013082302A1 (en) 2013-06-06

Family

ID=47326417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067098 WO2013082302A1 (en) 2011-11-30 2012-11-29 Agomelatine-urea complex and crystalline forms thereof

Country Status (3)

Country Link
EP (1) EP2771312B1 (en)
ES (1) ES2634243T3 (en)
WO (1) WO2013082302A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP4342879A1 (en) * 2022-09-21 2024-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Very efficient process for the preparation of agomelatine

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225442A (en) 1990-02-27 1993-07-06 Adir Et Compagnie Compounds having a naphthalene structure
EP1564202A1 (en) 2004-02-13 2005-08-17 Les Laboratoires Servier Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these
EP1752445A1 (en) 2005-08-03 2007-02-14 Les Laboratoires Servier New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it
EP1752443A1 (en) 2005-08-03 2007-02-14 Les Laboratoires Servier New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it
EP1752444A1 (en) 2005-08-03 2007-02-14 Les Laboratoires Servier New crystalline form IV of agometaline, the process for making it and pharmaceutical compositions containing it
DE102007030695A1 (en) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-crystal, useful e.g. to prepare a pharmaceutical formulation for the treatment of psychosis, neurological disorder and struma lymphomatosa, comprises an amino compound and urea as further component
EP2058296A1 (en) 2007-11-09 2009-05-13 Les Laboratoires Servier New crystalline form VI of agomelatine, method of preparation and pharmaceutical compositions thereof
CN101585779A (en) 2009-03-10 2009-11-25 上海医药工业研究院 New crystal form of Agomelatine, preparation method and use thereof
CN101723844A (en) 2009-11-21 2010-06-09 浙江华海药业股份有限公司 Agomelatine crystal form B, preparation method thereof and medicinal composition containing same
CN101955440A (en) 2009-07-17 2011-01-26 北京德众万全药物技术开发有限公司 Novel crystal form of agomelatine and preparation method thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225442A (en) 1990-02-27 1993-07-06 Adir Et Compagnie Compounds having a naphthalene structure
EP1564202A1 (en) 2004-02-13 2005-08-17 Les Laboratoires Servier Novel process for synthesizing and a novel crystal form of agomelatin as well as pharmaceutical preparations containing these
EP2008993A1 (en) 2005-08-03 2008-12-31 Les Laboratoires Servier New crystalline form III of agomelatine, method of preparing same and pharmaceutical compositions containing same
EP1752443A1 (en) 2005-08-03 2007-02-14 Les Laboratoires Servier New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it
EP1752444A1 (en) 2005-08-03 2007-02-14 Les Laboratoires Servier New crystalline form IV of agometaline, the process for making it and pharmaceutical compositions containing it
EP2008994A1 (en) 2005-08-03 2008-12-31 Les Laboratoires Servier New crystalline form IV of agomelatine, method of preparing same and pharmaceutical compositions containing same
EP1752445A1 (en) 2005-08-03 2007-02-14 Les Laboratoires Servier New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it
EP2210872A1 (en) 2005-08-03 2010-07-28 Les Laboratoires Servier New crystalline form III of agometalin, the process for its preparation and pharmaceutical compositions containing it
EP2277857A2 (en) 2005-08-03 2011-01-26 Les Laboratoires Servier New crystalline form V of agomelatine, method of preparing same and pharmaceutical compositions containing same
DE102007030695A1 (en) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-crystal, useful e.g. to prepare a pharmaceutical formulation for the treatment of psychosis, neurological disorder and struma lymphomatosa, comprises an amino compound and urea as further component
EP2058296A1 (en) 2007-11-09 2009-05-13 Les Laboratoires Servier New crystalline form VI of agomelatine, method of preparation and pharmaceutical compositions thereof
CN101585779A (en) 2009-03-10 2009-11-25 上海医药工业研究院 New crystal form of Agomelatine, preparation method and use thereof
CN101955440A (en) 2009-07-17 2011-01-26 北京德众万全药物技术开发有限公司 Novel crystal form of agomelatine and preparation method thereof
CN101723844A (en) 2009-11-21 2010-06-09 浙江华海药业股份有限公司 Agomelatine crystal form B, preparation method thereof and medicinal composition containing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAI-LI ZHENG ET AL: "Structures of Polymorphic Agomelatine and Its Cocrystals with Acetic Acid and Ethylene Glycol", CRYSTAL GROWTH & DESIGN, ACS, WASHINGTON, DC, US, vol. 11, 2 February 2011 (2011-02-02), pages 466 - 471, XP002658583, ISSN: 1528-7483, [retrieved on 20110106], DOI: 10.1021/CG101234P *
YAN YAN ET AL: "Improving the Solubility of Agomelatine via Cocrystals", CRYSTAL GROWTH & DESIGN, vol. 12, no. 5, 2 May 2012 (2012-05-02), pages 2226 - 2233, XP055028201, ISSN: 1528-7483, DOI: 10.1021/cg201423q *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
WO2019072866A1 (en) 2017-10-09 2019-04-18 Krka, D.D., Novo Mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP4342879A1 (en) * 2022-09-21 2024-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Very efficient process for the preparation of agomelatine

Also Published As

Publication number Publication date
EP2771312B1 (en) 2017-05-31
ES2634243T3 (en) 2017-09-27
EP2771312A1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
EP3524606A1 (en) Co-crystals of ibrutinib with carboxylic acids
EP1962600B1 (en) Metronidazole cocrystals
BR112017023740B1 (en) SOLID FORM, PROCESS FOR PREPARING A SOLID FORM, PHARMACEUTICAL COMPOSITION AND USE OF A SOLID FORM
CA2767489A1 (en) A crystalline form of posaconazole
WO2012051246A1 (en) Tapentadol hydrobromide and crystalline forms thereof
EP3743405B1 (en) Crystalline siponimod fumaric acid and polymorphs thereof
EP3344607A1 (en) Solid state forms of selexipag
JP2011503185A (en) Polymorphic form of aliskiren hemifumarate and its preparation process
WO2014008270A1 (en) Solid state form of vemurafenib choline salt
EP3430004B1 (en) Solid state forms of nilotinib salts
EP2771312B1 (en) Agomelatine-urea complex and crystalline forms thereof
EP3321267A1 (en) Crystalline forms of 2-[1-ethylsulfonyl-3-[7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile salts and preparation thereof
EP2551257A1 (en) Co-crystals of agomelatine with co-crystal-formers
WO2012071425A1 (en) Solid state forms of sorafenib besylate, and processes for preparations thereof
WO2016172333A1 (en) A solid state form of perampanel
JP6761564B2 (en) L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of L-proline compound
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
US8729130B2 (en) Methods of using novel solid forms of tacedinaline
EP2507250A1 (en) Solid state forms of fosamprenavir calcium salt and process for preparation thereof
JP2020535192A (en) Crystal form of lenalidomide
WO2015085971A1 (en) Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
WO2016004911A1 (en) A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
WO2012003413A1 (en) Novel solid forms of tacedinaline
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12799022

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2012799022

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012799022

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE